Test Price
2,800 AED✅ Home Collection Available
MLH1 Gene Mismatch Repair Cancer Syndrome Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified NGS & Sanger Confirmation.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed genetic counsellors.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
- UAE Regulatory Compliance: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, and Federal Decree-Law No. 4 of 2016 on Medical Liability.
Test Overview & Methodology
This NGS test screens the entire MLH1 gene for germline mutations linked to Lynch syndrome, a hereditary cancer predisposition syndrome. By identifying pathogenic variants early, patients can access life-saving surveillance and preventive strategies.
| Feature | Our Test (Precision Genetic Hub) | Closest Alternative (Legacy Sanger) |
|---|---|---|
| Methodology | NGS with full gene coverage + MLPA for large rearrangements | Sanger sequencing of select exons only |
| Turnaround Time | 3–4 Weeks (expedited available) | 6–8 Weeks |
| Sensitivity / Detection Rate | >99.9% for SNVs, indels, CNVs (ISO-validated) | ~85% (misses deep intronic and large rearrangements) |
| Clinical Interpretation | DHA-licensed report with ACMG 2020 classification & hereditary cancer risk analysis | Generic lab report without personalised risk counselling |
Physician Insight & Safety Protocols
"A positive MLH1 finding indicates a hereditary predisposition to Lynch syndrome, not an active cancer diagnosis. Proactive surveillance and a multidisciplinary care approach are essential for managing this inherited risk effectively."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medical Advisory – Medication Stability
This genetic test evaluates inherited cancer susceptibility. Do not alter any prescribed medications without consulting your physician.
Exclusion Criteria & Emergency Red Flags
- Not suitable for acute leukemia diagnosis or somatic tumour profiling.
- Do not use as a standalone pharmacogenomic test for chemotherapy selection.
- If you experience sudden abdominal pain, rectal bleeding, or jaundice, seek emergency care immediately – these symptoms require urgent evaluation unrelated to this test.
- Positive result warrants urgent referral to oncology and gastroenterology for colonoscopic surveillance from age 20–25.
Patient FAQ & Clinical Guidance
1. What is the MLH1 gene test and what does it detect?
This test identifies inherited pathogenic variants in the MLH1 gene associated with Lynch syndrome. A positive result indicates a significantly elevated lifetime risk for colorectal, endometrial, and other cancers, enabling tailored surveillance and preventive measures.
2. How is the sample collected for this genetic test?
A DHA-licensed phlebotomist collects a small peripheral whole blood sample (3–5 mL in EDTA tube) at your home using an ISO-certified cold-chain kit. The procedure is minimally invasive, follows strict infection control protocols, and is available daily from 8 AM to 11 PM.
3. Will my genetic data remain confidential under UAE law?
Yes, your DNA sequence and clinical data are encrypted and stored in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. No third-party sharing occurs without your explicit consent.
UAE Regulatory & Data Privacy Adherence
Data Protection: All genetic and personal data are processed under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL). Your information is encrypted, access-controlled, and never shared with third parties without explicit consent.
Healthcare Technology Compliance: This test fully adheres to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring secure electronic health records and telemedicine protocols.
Medical Liability: Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing your rights throughout the testing process.
Clinical & Logistical Metadata
| Test Name | MLH1 Gene Mismatch Repair Cancer Syndrome Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks (expedited available) |
| Sample Type / Matrix | Peripheral Whole Blood (3–5 mL in EDTA tube) |
| Methodology Used | Next-Generation Sequencing (NGS) with full gene coverage, MLPA for large rearrangements, and Sanger confirmation |
| ICD-10-CM Code | Z15.09, Z80.0 |
| LOINC Code | 21629-9 |
| DHA Facility License & Laboratory Address | License No. 1143 — Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians